Skip to content
Expleo Solutions logo

Expleo Solutions

EXPLEOSOL NSE
₹822.40 −7.15 (−0.86%)
P/E
9.27
View as Markdown
MCP
Close 4 Nov 2026 ₹822.40 −172.80 −17.4% 1Y
Start ₹995.20

Key Fundamentals

MicrocapIT - ServicesInformation Technology

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
24.20%
Debt to Equity
0.01
EPS (TTM)
₹88.75
Book Value
₹500.21
Market Cap
—
P/E (TTM)
9.27
P/B
1.64
ROE
18.70%
Dividend Yield
13.26%
EBITDA
₹208 Cr
52W High
₹1,175.10
52W Low
₹640.00
Day Range
₹814.00 – ₹842.40
Volume
11,867

Peer Comparison

Information Technology › IT Enabled Services

Expleo Solutions peer comparison
L&T Technology Services
₹4,133.5033.20₹45,364 Cr6.190.47%21.50%26.70%₹11,565 Cr₹1,322 Cr
Inventurus Knowledge Solutions
₹1,750.4039.33₹29,871 Cr10.730.00%31.40%31.50%₹3,347 Cr₹764 Cr
Tata Technologies
₹652.4547.55₹26,704 Cr6.911.81%16.30%20.90%₹5,926 Cr₹558 Cr
Netweb Technologies
₹4,062.3088.56₹24,520 Cr11.480.07%32.80%37.50%₹2,702 Cr₹260 Cr
Affle 3i
₹1,623.9047.83₹22,921 Cr5.070.00%13.80%16.80%₹2,836 Cr₹478 Cr
Sagility
₹43.5920.56₹20,233 Cr1.990.35%10.60%13.40%₹7,617 Cr₹994 Cr
ESDS Software Solution
₹1,193.6091.82₹14,545 Cr10.890.00%24.90%30.20%₹537 Cr₹134 Cr
Expleo Solutions (this company)
₹822.409.27₹1,287 Cr1.6413.26%18.70%24.20%₹1,140 Cr₹138 Cr
Median 8 companies₹1,408.7543.44₹23,720 Cr6.550.21%20.10%25.45%₹3,092 Cr₹518 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

69 Strong

Data confidence 100/100

Category scores

Quality
67
Strong
Returns, margins, earnings quality 22% weight
Valuation
89
Strong
Cheap vs sector & own history 24% weight
Growth
31
Poor
Sales & profit trajectory 9% weight
Financial Health
82
Strong
Solvency, leverage, coverage 9% weight
Momentum
52
Average
Trend strength, vol-adjusted 12% weight
Ownership
70
Strong
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

2
  • Company has reduced debt.
  • Company is almost debt free.

No weaknesses listed

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bearish1171
OscillatorsBearish270
Moving AveragesStrong Bearish901

Key readings

RSI (14)
44.15
Neutral
MACD (12,26,9)
−14.59
Bearish
SMA (50)
863.38
Bearish
SMA (200)
835.70
Bearish

As of

Analyst Rating

Based on 1 analysts
BUY100%

1 of 1 analyst rates Buy, 0 Hold, 0 Sell.

As of

BUY
1
100%
HOLD
0
0%
SELL
0
0%

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y+15.42%
5Y+29.78%
3Y+7.06%
1Y+8.10%
TTM+10.36%

Net profit

Net profit growth by window
10Y+12.86%
5Y+19.92%
3Y−2.55%
1Y+20.39%
TTM+39.39%

Operating cash flow

Operating cash flow growth by window
10Y+7.45%
5Y+12.51%
3Y+72.96%
1Y−33.52%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y−5.11 pp
5Y−7.92 pp
3Y−6.81 pp
1Y−0.86 pp
TTM+0.99 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹260 Cr
Mar 2018₹271 Cr
Mar 2019₹283 Cr
Mar 2020₹270 Cr
Mar 2021₹301 Cr
Mar 2022₹743 Cr
Mar 2023₹903 Cr
Mar 2024₹965 Cr
Mar 2025₹1,025 Cr
Mar 2026₹1,108 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹24.00 Cr
Mar 2018₹32.00 Cr
Mar 2019₹36.00 Cr
Mar 2020₹40.00 Cr
Mar 2021₹50.00 Cr
Mar 2022₹68.00 Cr
Mar 2023₹134 Cr
Mar 2024₹90.00 Cr
Mar 2025₹103 Cr
Mar 2026₹124 Cr

Analyst Forecasts

Forecast For
FY27 consensus · EPS
₹94.50 +18.3% vs FY26
Reported High Mean Low

Quarterly Results

₹ Cr
EXPLEOSOL quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
225
234
250
255
252
259
258
256
260
283
279
286
292
Expenses
192
200
212
221
213
217
219
216
230
236
233
244
249
Operating Profit
33
34
38
34
39
42
39
40
30
47
46
43
42
OPM %
15%
14%
15%
13%
15%
16%
15%
16%
11%
17%
16%
15%
15%
Other Income
2
2
11
2
2
13
3
5
7
13
−6
15
7
Interest
1
1
1
1
1
1
1
1
1
1
0
1
1
Depreciation
8
8
8
9
9
10
12
8
8
7
7
6
4
PBT
26
27
41
26
31
44
28
36
28
51
32
51
44
Tax %
22%
24%
16%
40%
23%
20%
30%
32%
28%
23%
31%
18%
23%
Net Profit
20
21
34
16
24
35
20
24
20
40
22
42
34
EPS (₹)
13.01
13.22
21.93
10.12
15.4
22.87
12.75
15.52
13.16
25.62
14.26
26.85
22.02

Profit & Loss

₹ Cr
EXPLEOSOL profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
214
264
260
271
283
270
301
743
903
965
1,025
1,108
1,140
Expenses
177
210
219
231
230
217
231
618
703
816
859
938
962
Operating Profit
37
54
41
40
53
53
70
124
200
149
166
170
178
OPM %
17%
20%
16%
15%
19%
20%
23%
17%
22%
15%
16%
15%
16%
Other Income
2
6
1
13
6
8
5
6
16
7
16
23
28
Interest
2
0
0
0
0
1
1
1
2
3
3
2
3
Depreciation
5
4
5
6
6
6
6
19
28
34
39
28
25
PBT
32
56
37
48
54
54
68
110
186
120
139
163
178
Tax %
32%
34%
36%
33%
32%
26%
26%
39%
28%
24%
26%
24%
—
Net Profit
22
37
24
32
36
40
50
68
134
90
103
124
138
EPS (₹)
20.53
34.68
22.29
29.86
33.79
38.92
49.2
66.01
131
58.27
66.52
79.89
88.75
Div. Payout %
117%
69%
108%
80%
0%
0%
0%
0%
6%
0%
75%
0%
—

Balance Sheet

₹ Cr
EXPLEOSOL balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
11
11
11
11
11
10
10
16
16
16
16
16
Reserves
91
98
116
118
128
142
192
379
515
596
620
761
Borrowings
10
0
0
0
0
0
7
15
26
26
30
8
Other Liabilities
54
73
43
63
53
62
56
185
174
128
165
145
Total Liabilities
165
182
171
191
192
214
264
594
730
765
831
929
Fixed Assets
24
25
27
22
19
26
25
108
142
131
113
73
CWIP
1
0
0
0
0
0
0
6
6
5
0
0
Investments
0
0
0
0
0
0
0
0
0
15
0
0
Other Assets
139
157
144
169
173
188
239
480
582
614
719
856
Total Assets
165
182
171
191
192
214
264
594
730
765
831
929

Cash Flow

₹ Cr
EXPLEOSOL cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
33
58
42
25
41
17
66
24
23
71
179
119
Investing
−6
11
−14
−18
24
−7
−44
3
−37
−33
−51
27
Financing
−11
−39
−31
−31
−26
−29
−3
−10
−7
−15
−87
−9
Net Cash Flow
16
30
−2
−23
38
−19
19
17
−21
24
41
137
Free Cash Flow
31
55
35
24
38
14
62
−1
−20
54
172
117
CFO/OP
118
133
136
99
121
55
124
42
35
76
133
95

Ratios

EXPLEOSOL financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
97
75
60
92
59
103
74
85
97
94
79
76
Cash Conversion Cycle
97
75
60
92
59
103
74
85
97
94
79
76
Working Capital Days
23
−7
8
21
15
50
48
46
93
112
67
68
ROCE %
29%
51%
31%
38%
40%
38%
39%
36%
39%
20%
21%
24%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Expleo Solutions insights

69 extracted metrics across FY12–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 71.05%
  • Public 23.46%
  • Others 4.94%
  • DIIs 0.39%
  • FIIs 0.16%

No promoter shares pledged as of Sep 2026

Change vs previous quarter

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

  • Q1 FY27 concall · Aug 2026
    PPT
  • Q4 FY26 concall · May 2026
    Transcript PPT
  • Q3 FY26 concall · Feb 2026
    PPT
  • Q2 FY26 concall · Nov 2025
    Transcript PPT
  • Q1 FY26 concall · Aug 2025
    PPT

Frequently Asked Questions about Expleo Solutions

What does Expleo Solutions Ltd do?
Expleo Solutions Ltd is an India-based software service provider primarily delivering software validation and verification services to the BFSI industry worldwide.
Where is Expleo Solutions Ltd (EXPLEOSOL) listed?
Expleo Solutions Ltd trades as EXPLEOSOL on the NSE and under code 533121 on the BSE.
Which sector does Expleo Solutions Ltd belong to?
Expleo Solutions Ltd is classified under the Information Technology sector, in the IT Enabled Services industry.
What is the PE ratio of Expleo Solutions Ltd?
Expleo Solutions Ltd trades at a PE ratio of 9.27 as of 4 Nov 2026, on earnings per share of ₹88.75, against a book value of ₹500.21 per share.
What is the 52-week high and low of Expleo Solutions Ltd?
Over the last 52 weeks Expleo Solutions Ltd has traded between ₹640 and ₹1,175.1 as of 4 Nov 2026.
Does Expleo Solutions Ltd pay dividends?
Expleo Solutions Ltd has a dividend yield of 13.26%.
What is the Return on Equity (ROE) of Expleo Solutions Ltd?
Expleo Solutions Ltd reported a return on equity of 18.70%. Its debt-to-equity ratio is 0.01.

Company Information

Expleo Solutions Ltd is an India-based software service provider primarily delivering software validation and verification services to the BFSI industry worldwide.

Website investors.expleo.com
CEO Mr. Phani Tangirala
Employees 3,948
Listed 26 Oct 2009
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/EXPLEOSOL.md for Expleo Solutions Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More IT Services stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month